The Monrovia, Calif.-based company said the registration will allow it to offer and sell up to $200 million in securities, including common stock, preferred stock, debt securities and warrants.
Staar Surgical said it has filed the registration statement with the SEC but that the registration has not yet become effective, according to an SEC filing.
Earlier this week, Staar Surgical said it won CE Mark approval in the European Union for its Evo+ Visian ICL intraocular lens with Aspheric Optic technology, and reported that a presbyopia study of the device is underway.
The company’s EVO+ Visian ICL is the company’s next-gen lens, designed to be surgically implanted and operate with the patient’s eye to correct vision. The lens is designed to be positioned inside the eye between the iris and natural lens where it stays indefinitely.